GleamWall
中文EN

CTXR Citius Pharmaceuticals, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1506251 · Fiscal year ends 09/30

Financial factors as of 2026-06-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-11.1%
TTM EPS YoY64.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-70.3%
ROA-34.3%
ROIC (approx.)-89.3%
Asset turnover—

Leverage & solvency

Liabilities / assets46.6%
Debt / equity0.00x
Current ratio0.84x
Interest coverage-127.24x

Cash quality & payout

Operating cash flow / net income0.75x
Accruals ratio-8.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY2025*2025-09-30FY2024*2024-09-30FY20232023-09-30FY20222022-09-30FY2021*2021-09-30
Income statement
Revenue———$90,000$90,000
R&D expense$9.16M$11.91M$14.82M$17.66M$12.24M
SG&A expense$18.53M$18.25M$15.30M$11.75M$9.84M
Operating income-$38.53M-$42.00M-$36.73M-$33.32M-$23.53M
Interest expense$267,782———$10,839
Pretax income-$38.68M-$38.85M-$31.97M-$33.06M-$23.05M
Income tax$1.06M$576,000$576,000$576,000$1,233
Net income-$37.43M-$39.14M-$32.54M-$33.64M-$23.05M
EBITDA—-$41.99M-$36.73M-$33.31M-$23.53M
EPS (basic)-3.38-5.97-5.57-0.23-0.23
EPS (diluted)-3.38-5.97-5.57-0.23-0.23
Weighted avg. shares (diluted)11.07M6.73M6.05M146.08M108.60M
Balance sheet
Cash & equivalents$4.25M$3.25M$26.48M$41.71M$70.07M
Inventory$22.29M$8.27M———
Current assets$27.93M$14.22M$34.37M$44.56M$72.81M
PP&E, net——$1,432$4,100$7,023
Goodwill$9.35M$9.35M$9.35M$9.35M$9.35M
Total assets$130.94M$116.65M$103.61M$114.00M$142.43M
Current liabilities$44.91M$35.81M$5.78M$4.53M$3.98M
Total liabilities$53.41M$42.55M$12.18M$10.57M$9.65M
Shareholders' equity$67.55M$70.08M$90.83M$102.83M$132.18M
Shares outstanding18.07M7.25M6.35M146.21M145.98M
Cash flow statement
Operating cash flow-$26.55M-$28.20M-$29.06M-$28.36M-$24.25M
Capital expenditure————$6,938
Free cash flow————-$24.26M
Investing cash flow-$5.75M-$5.00M——-$40.01M
Financing cash flow$33.30M$9.97M$13.83M—$120.47M
Depreciation & amortization—$1,432$2,668$2,923$1,492
Stock-based compensation$10.84M$11.84M$6.62M$3.91M$1.45M

Free plan shows the latest 5 periods; Pro shows all 18 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-19 06:28.